Janet Dancey

Canadian Cancer Trials Group, Queen’s University, Kingston, Canada

Biography

 

Department of Oncology, Doctor of Medicine, Queen's University Omics, Phase II Clinical Trial, Next Generation Sequencing, Lung Cancer, Biomarker Discovery
She has contributed to publish 200+ research works in abnove fields

Publications

Final Efficacy Results of a Randomized Phase II Study of Recombinant Interleukin-21 Compared to Dacarbazine in Patients with Recurrent or Metastatic Melanoma

Objective: Interleukin-21(IL-21) is a T-cell derived cytokine with antitumour activity dependent on NK cells or CD8+ T cells. A previous phase II study demonstrated an overall response rate (ORR) of 22.5% in previously untreated patients with metastatic melanoma. We conducted a multi-centre randomized phase II study in metastatic melanoma patients ... Read More»

Teresa M. Petrella, Catalin Mihalcioiu, Jose Monzon, Elaine McWhirter, Karl Belanger, Kerry J. Savage, Xinni Song, Omid Hamid, Tina Cheng, Mary Davis, Christopher W. Lee, Alan Spatz, Linda Hagerman, Bingshu E. Chen and Janet Dancey

: J Oncol Res Treat 4: 132

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article